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Abstract  
Hyperactivity of the renin-angiotensin system (RAS) is associated with the pathogenesis of 
Alzheimer’s disease (AD) believed to be mediated by angiotensin-II (Ang-II) activation of the 
angiotensin type 1 receptor (AT1R).  We previously showed that angiotensin-converting enzyme-1 
(ACE-1) activity, the rate-limiting enzyme in the production of Ang-II, is increased in human post-
mortem brain tissue in AD. Angiotensin-III (Ang-III) activates the AT1R and angiotensin type-2 
receptor (AT2R) but its potential role in the pathophysiology of AD remains unexplored. We 
measured Ang-II and Ang-III levels by ELISA, and the levels and activities of aminopeptidase-A (AP-A) 
and aminopeptidase-N (AP-N) (responsible for the production and metabolism of Ang-III 
respectively) in human post-mortem brain tissue in the mid-frontal cortex (Brodmann area 9) in a 
cohort of AD (n=90) and age-matched non-demented controls (n=59), for which we had previous 
measurements of ACE-1 activity, Aβ level and tau pathology (also in the mid-frontal cortex). We 
found that both Ang-II and Ang-III levels were significantly higher in AD compared to age-matched 
controls and that Ang-III, rather than Ang-II, was strongly associated with Aβ load and tau load. 
Levels of AP-A were significantly reduced in AD but AP-A enzyme activity was unchanged whereas 
AP-N activity was reduced in AD but AP-N protein level was unchanged. Together, these data 
indicate that the APA/Ang-III/APN/Ang-IV/AT4R pathway is dysregulated and that elevated Ang-III 
could contribute to the pathogenesis of AD. 
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Introduction 
It is now well established that there is a local-acting renin-angiotensin-system (RAS) within 
the brain that functions independently from the systemic RAS [1-4] and that hyperactivity of brain 
RAS is associated with the pathogenesis of Alzheimer’s disease (AD) [5]. Most of the deleterious 
effects of the brain RAS in AD are believed to be associated with elevated Ang-II levels and its 
subsequent over-activation of angiotensin receptor type-1 (AT1R), commonly referred to as the 
classical axis of RAS (reviewed in [5]). Infusion of Ang-II increased both amyloid-beta (Aβ) (via 
increased amyloidogenic processing of APP) and tau pathology, and reduced cognitive performance 
in ageing Sprague Dawley rats [6, 7]. We have previously reported that angiotensin-converting 
enzyme-1 (ACE-1), the rate-limiting enzyme in the production of Ang-II, is increased in AD in human 
brain tissue [8, 9]. Epidemiological studies suggest that commonly prescribed anti-hypertensives that 
target brain RAS and thus reduce the activity of classical RAS (ACE-1 inhibitors and AT1R blockers) 
protect against cognitive decline and that re-purposing these drugs may have therapeutic potential 
in AD [10, 11].  
Angiotensin-III (Ang-III) is a heptapeptide produced following aminopeptidase-A (AP-A) (EC 
3.4.11.7) mediated cleavage of the Asp residue at the N-terminal of Ang-II [12-15]. Ang-III is a potent 
activator of AT1R and AT2R [16, 17]. Evidence from experimental animal models suggest that Ang-III 
shares many of the biological effects that are attributed to Ang-II and that Ang-III-mediated 
activation of AT1R is implicated in a host of responses including increased blood pressure [18-21], 
dysregulated drinking and salt intake [20], increased pituitary hormone release [22, 23] and 
increased vasopressin release [24]. Orally administered AP-A inhibitors, resulting in Ang-III reduction, 
are cardioprotective [25-28] suggesting that Ang-III, rather than Ang-II, may be the central effector 
protein in RAS (reviewed in [3]). Ang-III is metabolised by aminopeptidase-N (AP-N) (EC 3.4.11.2) to 
generate Ang IV [29], a peptide that via inhibition of insulin-regulated aminopeptidase (IRAP), is 
heavily implicated in learning and memory consolidation [30, 31]. This APA/Ang-III/APN/Ang-
IV/AT4R pathway remains poorly characterised within the brain and its potential role in AD is poorly 
understood. Recent studies indicate that serum and plasma AP-A and AP-N activities are reduced in 
early AD [32, 33]. 
In the present study, we have measured the levels of Ang-II and Ang-III, and the levels and activities 
of AP-A and AP-N (responsible for the metabolism of Ang-II and Ang-III respectively) in relation to Aβ 
and Tau pathology in AD. 
 
Materials and Methods  
Case selection 
Brain tissue was obtained from the South West Dementia Brain Bank, University of Bristol, 
with local research ethics committee approval. All brains had been subjected to detailed 
neuropathological assessment according to the NIA-AA guidelines [34] and AD pathology was a 
sufficient explanation for the dementia in these cases. We investigated 90 cases of AD and 59 age-
matched controls whose brains were from people who had no history of dementia and had 
undergone extensive neuropathological assessment and had few or absent neuritic plaques, a Braak 
tangle stage of III or less, and no other neuropathological abnormalities. All cases had previous 
measurements of ACE-1 activity [8, 35], total soluble (NP-40-extracted) and insoluble (Guanidine 
Hydrochloride (GuHcl)-extracted) Aβ levels [36], and tau load (area fraction of cerebral cortex 
immunopositive for ptau) [37, 38] within the mid-frontal cortex (Brodmann area 9). The cohorts 
were matched closely for age-at-death and post-mortem delay. The demographic data are 
presented in Table 1 and the MRC UK Brain Bank Network database identifiers are shown in 
Supplementary Table 1.  
Brain tissue 
The right cerebral cortex had been fixed in 10% formalin for a minimum of three weeks before the 
tissue was processed and paraffin blocks were taken for pathological assessment. The left cerebral 
hemisphere had been sliced and frozen at -80°C until used for biochemical assessment. For each 
case we dissected 200mg brain tissue from the mid-frontal cortex (Brodmann area 9) that was 
homogenised in a Precellys homogeniser (Stretton Scientific, Derbyshire, UK) as previously described 
[8, 9]. Brain homogenates were prepared in either 1% SDS lysis buffer (100uM NaCl, 10mM Tris pH 6, 
1μM phenylmethylsulfonyl fluoride (PMSF), 1μg/ml aprotinin (Sigma Aldrich) and 1% SDS in distilled 
water) or 0.5% triton-X100 lysis buffer (20mM Tris pH 7.4, 10% sucrose, 1μM PMSF, 1μg/ml 
aprotinin (Sigma Aldrich) and 0.5% triton X-100 in distilled water). The samples were centrifuged at 
13,000rpm and the clarified supernatants were aliquoted and stored at −80°C until required. Total 
protein was measured using the Total Protein kit (Sigma Aldrich, Dorset, UK) following 
manufacturer’s guidelines. Most brain tissue was obtained within 72 hours of death.  
Angiotensin-II sandwich ELISA 
Ang-II level was measured in brain tissue homogenates (in 1% SDS lysis buffer) using a commercially 
available sandwich ELISA (Abcam, UK) following manufacturer’s guidelines.  In brief, recombinant 
human Ang-II or brain tissue supernatants (50 µl + 50µl PBS) were added in duplicate to wells that 
had been pre-coated with an anti-human Ang-II specific antibody and incubated for 2 hours at room 
temperature. After a wash step, the plate was incubated for 2 hours with a biotinylated anti-Ang-II 
detection antibody at room temperature. The plate was again washed followed by 30 minutes 
incubation with streptavidin:horse radish peroxidase (strep:HRP). After a final wash, TMB substrate 
was added for 20 minutes in the dark and the absorbance was read at 450nm using a FLUOstar 
OPTIMA plate reader (BMG labtech, Aylesbury, Buckinghamshire, UK). The concentration of Ang-II 
was interpolated from a serial dilution of recombinant Ang-II (1,000-62.5pg/ml) and measured in 
duplicate for each case. Ang-II level is expressed as pg/mg total protein for each case. 
Angiotensin-III direct ELISA 
Ang-III level was measured in human brain tissue homogenates (in 1% SDS lysis buffer) using a direct 
ELISA. Recombinant human Ang-III (Sigma Aldrich, Dorset, UK) or human brain tissue homogenates 
(diluted 1 in 10 In PBS) were incubated for 2 hours in a clear high-binding capacity NUNC maxisorp 
plate (ThermoFisher Scientific, Waltham, MA, USA) at 26°C with shaking. The wells were washed 
five-times in PBS with 0.05% tween-20 and blocked for 1 hour in 1 % PBS: BSA (Sigma Aldrich, 
Dorset, UK). After another five washes, the wells were incubated with biotinylated anti-human Ang-
III (diluted to 2ug/ml in PBS) (Cloud-Clone, Wuhan, China) for 2 hours at 26°C with shaking, followed 
by a further wash step. The plate was incubated with strep:HRP (1:200) in PBS:0.01% Tween-20 at 
room temperature for 20 minutes in the dark. TMB substrate (R&D systems) was added after a 
further wash and left to develop in the dark for 20 minutes. Absorbance at 450nm was read 
following the addition of 2N sulphuric acid (‘stop’ solution) using a FLUOstar OPTIMA plate reader 
(BMG labtech, Aylesbury, BUCKS, UK). Ang-III concentrations were interpolated from a standard 
curve generated by serially diluting recombinant human Ang-III (20,000-312.5pg/ml) and were 
measured in duplicate. Ang-III level is expressed as ng/mg total protein. The assay showed minimal 
cross reactivity with a number of closely-related peptides including Ang I, Ang-II and Ang 1-7. 
Aminopeptidase-A sandwich ELISA 
AP-A level was measured in brain tissue homogenates (in 1% SDS lysis buffer) using a commercially 
available competitive sandwich ELISA (FIRELISA; Human GluAP Cat. No. ELISAHu004197). In brief, 
brain tissue homogenates (diluted 1 in 25 in PBS) or recombinant human AP-A was added together 
with biotinylated antigen for 1 hour at 37°C. After 5 washes with the proprietary wash buffer, 
streptavidin-HRP was added to each well for 1 hour at 37°C. After a further five washes, TMB 
chromogen was added to each well and incubated for 20 minutes in the dark. Absorbance at 450nm 
was read after the reaction was stopped using 2N sulphuric acid using a FLUOstar OPTIMA plate 
reader (BMG labtech, Aylesbury, BUCKS, UK). AP-A levels were measured in duplicate for each case 
and were interpolated from a serial dilution of recombinant human AP-A (32-2ng/ml). AP-A level is 
expressed as ng/mg total protein. 
Aminopeptidase-A enzyme activity assay 
AP-A enzyme activity was measured in brain tissue homogenates (in 0.5% triton X-100 lysis buffer) 
using a fluorogenic peptide substrate, H-Glu-AMC-OH (AMC = 7-amido-4-methylcoumarin) (200uM) 
(Bachem, Bubendorf, Switzerland). The assay was performed in Nunc F16 black maxisorp 96-well 
plates (ThermoFisher Scientific, Waltham, MA, USA). A series of preliminary experiments were 
performed to test a range of substrate concentrations (400-25μM) using a serial dilution of 
recombinant human AP-A (400 – 3.2 ng/ml) over an extended reaction time i.e. fluorescence was 
read every 5 minutes up to 30 minutes and then again at 1 and 2 hours. H-Glu-AMC-OH at 200μM 
produced the highest fluorescent signal that became saturated at one hour i.e. total cleavage of 
substrate was observed. All subsequent experiments were performed using H-Glu-AMC-OH at 
200μM and the reaction was allowed to proceed for 1 hour at 37°C. Brain tissue homogenates 
(triton X-100) (100ug total protein), or recombinant AP-A (serially diluted to produce a standard 
curve (400 – 3.2 ng/ml)) were diluted in assay buffer (25mM Tris pH 8.0, 50mM CaCl2, 200uM NaCl) 
and incubated in the presence of amastatin-HCl a general aminopeptidase inhibitor [39] (10uM) 
(Enzo Life Sciences, Exeter, UK), or assay buffer alone, for 10 mins at 37°C prior to the addition of H-
Glu-AMC-OH (200uM diluted in assay buffer). The reaction was incubated at 37°C for 1 hour in the 
dark and fluorescence was read at an excitation/emission of 390/450nm using a using a FLUOstar 
OPTIMA plate reader (BMG labtech, Aylesbury, BUCKS, UK). Enzyme activities are expressed as 
mMol of H-Glu-AMC-OH hydrolyzed per hour per mg of total protein (using the 7-amido-4-
methylcoumarin (AMC) (Sigma Aldrich, Dorset, UK) as a reference).  
Aminopeptidase-N sandwich ELISA 
AP-N level was measured in brain tissue homogenates (in 1% SDS lysis buffer) using a commercially 
available ELISA kit (AP-N duoset, Cat no. DY3815) (R&D systems, Cambridge, UK). High-binding 
capacity NUNC Maxisorp 96-well plates (ThermoFisher Scientific, Waltham, MA, USA) were coated 
with a human anti-AP-N capture antibody diluted in PBS (0.8ug/ml) overnight at room temperature. 
The wells were washed five time in PBS/0.05% tween-20 and blocked with 1% PBS: BSA for 1 hour at 
room temperature. The wells were washed again and recombinant human AP-N (20-0.3125 ng/ml), 
or brain tissue (diluted 1 in 20 in PBS), was incubated for 2 hours at room temperature. After a 
further five washes, the wells were incubated with streptavidin:HRP  (diluted 1:200) (R&D systems) 
for 20 mins in the dark. The wells were washed again and TMB substrate (100ul) (R&D systems) was 
added and left in the dark for 20 minutes. Upon addition of 2N sulphuric acid (50ul ‘stop’ solution) 
absorbance was read at 450nm in a FLUOstar OPTIMA plate reader (BMG labtech, Aylesbury, BUCKS, 
UK). The concentration of AP-N was interpolated from a serial dilution of recombinant human AP-N 
and AP-N levels were measured in duplicate for each case and expressed as ng/mg total protein.  
Aminopeptidase-N enzyme activity  
AP-N enzyme activity was measured in brain tissue homogenates (in 0.5% triton X-100 lysis buffer) 
using an immunocapture-based activity assay using the fluorogenic peptide substrate, H-ALA-AMC 
(AMC = 7-amido-4-methylcoumarin) (200uM) (Bachem, Bubendorf, Switzerland). A black high 
binding-capacity Nunc maxisorp 96-well plate (ThermoFisher Scientific, Waltham, MA, USA) was 
coated overnight at room temperature with capture antibody from the AP-N duoset ELISA kit 
(0.8ug/ml)(R&D systems, Abingdon, Oxford, UK). After five washes in 0.05% PBS:Tween-20 each well 
was blocked in 1% PBS:BSA for 1 hour at room temperature. After another wash step, a serial 
dilution of recombinant human AP-N (200 – 1.56 ng/ml) (R & D systems, UK) or brain tissue 
homogenates (125ug total protein) were incubated for 2 hours at room temperature. After another 
5 washes, wells were either incubated with betstatin-HCl (20uM) (Sigma Aldrich, Dorset, UK) diluted 
in assay buffer (50mM Tris, pH 7.0), or assay buffer alone, at 37°C for 10mins prior to the addition of 
H-ALA-AMC (200uM). A series of preliminary experiments were performed to test a range of H-ALA-
AMC concentrations (400-25μM) using a serial dilution of recombinant human AP-N (200 – 
12.5ng/ml) over an extended reaction time i.e. fluorescence was read every 5 minutes up to 30 
minutes and then again at 1 and 2 hours.  H-ALA-AMC at 200uM produced the highest fluorescent 
signal that became saturated at one hour i.e. total cleavage of substrate was observed. All 
subsequent experiments were performed using H-ALA-AMC (200uM), the reaction was allowed to 
proceed for 1 hour at 37°C, and fluorescence was read at excitation/emission at 390/450nm using a 
FLUOstar OPTIMA plate reader (BMG labtech, Aylesbury, Buckinghamshire, UK). AP-N enzyme 
activity is expressed as mMol of  H-ALA-AMC hydrolyzed per hour per mg of total protein (using the 
7-amido-4-methylcoumarin (AMC) as a reference). 
AP-A and AP-N immunohistochemistry 
Paraffin sections (7μm) were dewaxed in Clearene, dehydrated in 100% ethanol and immersed in 3% 
hydrogen peroxide in methanol for 30 minutes to block endogenous peroxidase activity. The tissue 
was washed in running tap water and sections were boiled in 9mM tri-sodium citrate, pH 6, for 5 
minutes, left to stand for 5 minutes, boiled again for 5 minutes and finally left to stand for 15 
minutes at room temperature. The sections were incubated with Vectastain blocking serum (horse) 
(ABC kit, Vector labs, Vector Labs, Peterborough, UK) then incubated overnight with primary 
antibody at room temperature: Rabbit polyclonal anti-ENPEP (Aminopeptidase A) (Cat no. 
HPA005128, Sigma Aldrich, Dorset, UK) was diluted 1 in 75 and mouse monoclonal CD13 (AP-N) (cat 
no. ab7417, Abcam, Cambridge, UK) was diluted 1 in 400. All sections were then incubated with 
biotinylated Universal Antibody followed by VectaElite ABC complex and with 3,3’-diaminobenzidine 
(DAB) for 7 minutes. After incubation with DAB, sections were washed in water and immersed in 
copper sulphate DAB enhancer for 4 minutes, counterstained with haematoxylin Gill II for 15 
seconds, dehydrated, cleared and mounted in Clearium. 
Statistical analysis 
Parametric statistical tests were used for comparisons between groups and ANOVA with Bonferroni 
post-hoc test was used for multiple-group comparisons. Pearson analysis was used to assess the 
correlation between pairs of variables. Statistical tests were performed using SPSS version 23. P-
values < 0.05 were considered statistically significant. 
 
Results 
Study cohort 
The control (mean age-at-death ± SD = 78.5 ± 10 years and post-mortem (PM) delay ± SD = 43.8 ± 36 
hours) and AD cohorts (mean age-at-death ± SD = 78.5 years ± 9.7 years and post-mortem delay ± SD 
= 45.0 hours ± 25 hours) were matched closely for age-at-death and PM delay (Table 1). Ang-II and 
Ang-III levels (Supplementary Figure 1), and AP-A and AP-N level and enzyme activity 
(Supplementary Figure 2) did not vary according to age-at-death or PM delay.  
The control and AD cohorts varied with regard to the ratio of male: female with a higher ratio of 
males in the control (F 22: M 37) and females in the AD group (F 55: M 35)  (Table 1). Ang-II and Ang-
III level did not differ between genders although a non-significant trend of higher Ang-II was 
observed in females compared to males in both the control and AD group (Supplementary Figure 3). 
Ang-III level, and AP-A and AP-N enzyme activity and protein levels were not influenced by gender 
(Supplementary Figure 3).  
 
Angiotensin II level is increased in Alzheimer’s disease and does not correlate with parenchymal Aβ 
and tau load 
Ang-II level was significantly elevated in AD (mean ± SEM = 58.30 ± 2.33 pg/mg total protein) 
compared with controls (mean ± SEM = 39.49 ± 3.34 pg/mg total protein) (P < 0.0001) (Fig. 1A). 
When the cases were stratified according to Braak tangle stage, an indicator of disease severity, Ang-
II level was significantly increased in Braak stage V-VI (mean ± SEM = 56.42 ± 2.62 pg/mg total 
protein) compared to Braak stage 0-II (mean ± SEM = 38.63 ± 3.40 pg/mg total protein) (P < 0.001) 
(Fig. 1B). Ang-II level was increased in Braak stage III-IV (mean ± SEM = 49.96 ± 4.45 pg/mg total 
protein) but was not significantly different to Braak stage 0-II. Ang-II level did not correlate with 
insoluble Aβ level (r = 0.12; P = 0.20) (Fig. 1C) or parenchymal tau load (r = 0.16; P = 0.06) (Fig. 1D). 
 
Angiotensin III level is increased in Alzheimer’s disease and correlates strongly with parenchymal Aβ 
and tau load 
Ang-III level was significantly elevated in AD (mean ± SEM = 154.79 ± 2.90 ng/mg total protein) 
compared with controls (mean ± SEM = 127.01 ± 3.27 ng/mg total protein) (P < 0.0001) (Fig. 2A). 
When the cases were stratified according to Braak tangle stage, an indicator of disease severity, the 
level of Ang-III was significantly increased in Braak stage V-VI (mean ± SEM = 157.49 ± 3.18 ng/mg 
total protein) compared to Braak stage 0-II (mean ± SEM = 127.66 ± 3.99 ng/mg total protein) (P < 
0.0001) (Fig. 2B). Ang-III level was unchanged between Braak stage 0-II and III-IV (mean ± SEM = 
134.19 ± 4.28 ng/mg total protein). A strongly significant positive correlation was observed between 
the level of Ang-III and the concentration of Aβ (r = 0.49, P < 0.0001) (Fig. 2C) and between Ang-III 
and parenchymal tau load (0.28, P < 0.01) (Fig. 2D). Multiple regression analysis (Ang-III as the 
dependent variable and Aβ and ptau load as the predictors) indicates that Aβ alone is a strong 
independent predictor of Ang-III (P < 0.0001) whereas ptau is not (P = 0.072). 
 
Aminopeptidase-A level is reduced in AD 
Aminopeptidase-A (AP-A) is the rate-limiting enzyme in the production of Ang-III. AP-A level was 
significantly reduced in AD (mean ± SEM = 1285.45 ± 47.35 ng/mg total protein) compared to 
controls (mean ± SEM = 1696 ± 66.35 ng/mg total protein) (P < 0.0001) (Fig. 3A) and was significantly 
lower in Braak stage V-VI (mean ± SEM = 1255.67 ± 47.96 ng/mg total protein) compared to Braak 
stage 0-II (mean ± SEM = 1732.5 ± 86.96 ng/mg total protein) (P < 0.0001). No difference was 
observed between Braak stage III-IV (mean ± SEM = 1632.52 ± 97.73 ng/mg total protein) and 0-II. 
Despite the reduction in AP-A level, a trend towards higher AP-A activity was observed in AD (mean 
± SEM = 2.11 ± 0.23 mMol/hour/mg protein) compared to controls (mean ± SEM = 1.73 ± 0.18 
mMol/hour/mg protein) (Fig. 3C) and in relation to Braak tangle stage (BS) (mean ± SEM = 1.75 ± 
0.20 mMol/hour/mg protein in BS 0-II; 1.92 ± 0.43 mMol/hour/mg protein in BS III-IV and 2.08 ± 0.24 
mMol/hour/mg protein in BS V-VI) (Fig. 3D) although neither reached statistical significance. 
 
Aminopeptidase-N level is unchanged but enzyme activity is reduced in AD 
AP-N level was unchanged in AD (mean ± SEM 55.85 ± 1.91 ng/mg total protein) compared to 
controls (mean ± SEM 53.16 ± 2.05 ng/mg total protein) (Fig. 4A) and did not vary according to Braak 
tangle stage (mean ± SEM 52.71 ± 2.40 ng/mg total protein in BS 0-II ; 53.2 ± 3.18 ng/mg total 
protein in BS III-IV and 56.27 ± 2.10 ng/mg total protein in BS V-VI) (Fig. 4B). AP-N activity was 
significantly lower in AD (mean ± SEM 2.24 ± 0.16 mMol/hour/mg total protein) compared with age-
matched controls (mean ± SEM 2.86 ± 0.22 mMol/hour/mg protein) (P < 0.05) (Fig. 3C). A trend 
towards reduced AP-N activity in relation to increasing Braak stage severity was observed (mean ± 
SEM 2.89 ± 0.25 mMol/hour/mg protein in BS 0-II; 2.39 ± 0.35 mMol/hour/mg protein and 2.24 ± 
0.17 mMol/hour/mg protein in BS V-VI), however, there were no significant differences between 
Braak tangle stage groups. 
 
Aminopeptidase-A localisation in human brain tissue 
AP-A immunolabeling of the vasculature was observed within the temporal neocortex and subiculum 
in both AD and controls (Figure 5). Perivascular AP-A labeling was also present in areas of focal white 
matter ischaemic damage (Figure 5). AP-A labeling of macrophages and microglia was observed, 
particularly in association with Aβ plaques and occasional neuronal labeling was present in both AD 
and controls. A similar staining pattern was observed in the frontal and parietal neocortex (not 
shown). 
 
Aminopeptidase-N localisation in human brain tissue 
AP-N neuronal labeling was observed within the frontal neocortex, CA2 region of the hippocampus, 
temporal neocortex and parietal neocortex in AD (Figure 6a-d). A similar distribution of AP-N was 
observed in controls, albeit with much lower intensity (Figure 6e-h). AP-N immunolabeling was not 
observed in the vasculature. 
 
Discussion 
 In the present study we measured Ang-II and Ang-III levels in relation to pathological 
markers of Alzheimer’s disease. Our data indicate that Ang-II and Ang-III levels are both increased in 
AD but that Ang-III levels correlate strongly with parenchymal Aβ and tau load whereas Ang-II levels 
did not. We also found dysregulation of the APA/Ang-III/APN/Ang-IV/AT4R pathway in AD. AP-A 
(responsible for the conversion of Ang-II to Ang-III) levels were significantly reduced in AD but 
enzyme activity was unaltered.  AP-N (responsible for the conversion of Ang-III to Ang-IV) activity 
was reduced in AD despite AP-N protein levels remaining unchanged. Together, these data suggest 
dysregulation of the APA/Ang-III/APN/Ang-IV/AT4R pathway might contribute to elevated Ang-III in 
AD due to increased conversion of Ang-II to Ang-III and reduced metabolism of Ang-III to Ang-IV. 
Together these data suggest that Ang-III level, and the enzymes involved in its processing, may 
contribute to the pathogenesis of AD. 
Hyperactivity of the classical axis of brain RAS (ACE-1/Ang-II/AT1R) via Ang-II-mediated 
signalling through the AT1R receptor is implicated in the pathogenesis of AD (reviewed in [5]). We 
have previously reported that ACE-1 activity (rate-limiting in Ang-II production) is increased in 
human post-mortem brain tissue in association with higher parenchymal Aβ load [8]. In the present 
study, we measured Ang-II and Ang-III levels in human post-mortem brain tissue in AD. Ang-II was 
elevated in AD but did not correlate with Aβ and tau levels. In contrast, Ang-III was significantly 
increased in AD and correlated strongly with both Aβ level and parenchymal tau load. Ang-III has 
been shown to bind with equipotency to AT1r and AT2r and share many of the physiological 
functions of Ang-II and studies have shown that orally administered AP-A inhibitors, which 
presumably reduce the level of Ang-III, are cardio-protective [25-28]. It is conceivable that Ang-III, 
rather than Ang-II, may be the central effector in the classical axis of brain RAS.  
We have also explored the pathways responsible for Ang-III metabolism, commonly referred 
to as the APA/Ang-III/APN/Ang-IV/AT4R pathway, which involves AP-A-mediated conversion of Ang-
II to Ang-III and further downstream processing of Ang-III by AP-N to Ang-IV. Our data suggest that 
increased Ang-III is associated with a non-significant trend towards increased AP-A activity i.e. 
increased conversion of Ang-II to Ang-III, in combination with significantly reduced AP-N activity i.e. 
reduced conversion of Ang-III to Ang-IV.  
It is currently unclear why there is a discrepancy between AP-A level (significantly reduced) 
and activity (non-significantly elevated) but this could indicate that there is post-translational 
modification in AD that enhances that activity of AP-A relative to the reduced AP-A protein level. 
These findings in brain tissue are in contrast to previous studies showing a gender-specific reduction 
(lower in males) in plasma and serum AP-A activity in AD [32, 33]; whether this is due to differences 
between the brain and periphery (as we have also observed for ACE-1 activity in brain tissue [8, 9, 
35]) remains unknown. Our immunohistochemical studies revealed that AP-A was mostly localised 
within microglia surrounding Aβ plaques in AD suggesting that there may be upregulation of a 
specific pool of AP-A in conjunction with an immune response associated with AD pathology. 
Alternatively, the trend towards increased AP-A activity in AD may simply reflect a compensatory 
response of AP-A in the presence of increasing Ang-II level. AP-A generates highly amyloidogenic and 
neurotoxic N-terminal truncated and pyroglutamated (AβpE3) Aβ42 species that could also 
contribute directly to AD pathogenesis [40, 41].  
AP-N activity was significantly reduced in AD in contrast to protein levels that either 
remained unchanged (determined by ELISA) or appeared to be elevated (immunohistochemical 
analysis). A reduction in AP-N activity could however potentially mediate reduced conversion of Ang-
III to Ang-IV resulting in elevated Ang-III level, which would not only impact on disease pathology but 
could also influence downstream signalling pathways involved in cognition - Ang-IV mediated 
inhibition of its receptor IRAP is heavily implicated in learning and memory processes [30, 31]. Serum 
and plasma AP-N activities are also reduced in AD [32, 33]. Together, our data indicate that Ang-III 
may be increased in AD as a result of dysregulation of the APA/Ang-III/APN/Ang-IV/AT4R pathway 
and could contribute not only to disease pathology but also to memory impairment.  
Emerging data has identified a number of regulatory pathways within brain RAS that are 
involved in the metabolism of Ang-II and counter-regulate the activity of the ‘classical’ RAS axis 
(reviewed in [4]). ACE-2 converts Ang-II to Ang 1-7, which via the MAS receptor counter-regulates 
the actions of the classical axis, known as the ACE2/Ang(1-7)/MASR pathway (reviewed in [42, 43]). 
We recently showed that ACE-2 activity is highly significantly reduced in AD and is inversely 
correlated with both Aβ level and tau parenchymal load [44]. Ang 1-7 (via the MAS receptor) is also 
implicated in long-term potentiation [45] and therefore loss of the activity within the ACE2/Ang(1-
7)/MASR pathway may not only be associated with disease pathology, but as for Ang-IV, may 
adversely impact on learning and memory processes.   
These data indicate that elevated Ang-III level in AD is strongly linked with disease pathology 
and is possibly associated with dysregulation of the APA/APN/Ang-IV/AT4R pathway within brain 
RAS. Longitudinal studies, such as those described by Gard et al. [32] who measured changes in 
serum aminopeptidases activity in healthy and mild-moderate AD at various stages of disease, will 
be useful in determining whether changes within these RAS pathways contribute to the early 
pathological changes in AD. 
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Figure Legends 
Figure 1. Angiotensin-II (Ang-II) level is increased in the mid-frontal cortex in Alzheimer’s disease 
(AD). (A) Bar chart showing significantly elevated Ang-II levels in AD compared to age-matched 
controls (P < 0.0001 using an unpaired t-test). (B) Bar chart showing increased Ang-II level in relation 
to disease severity, indicated by Braak tangle stage. Angiotensin-II level was significantly increased in 
Braak stage V-VI compared to 0-II (P < 0.001 using a one-way ANOVA with Bonferroni post-hoc 
analysis). In A and B the bars represent the mean and SEM. (C-D) Scatterplots showing a trend 
towards positive correlations between Ang-II level and (C) guanidine-HCl-extracted insoluble 
amyloid-beta (Aβ) level and (D) parenchymal tau load. The best-fit linear regression lines (inner line) 
and 95% confidence intervals are superimposed. Each dot represents a single case. The green circles 
indicate controls and the red circles indicate AD cases. 
Figure 2. Angiotensin-III (Ang-III) level is increased in the mid-frontal cortex in Alzheimer’s disease 
(AD). (A) Bar chart showing significantly elevated Ang-III levels in AD compared to age-matched 
controls (P < 0.0001 using unpaired t-test). (B) Bar chart showing increased angiotensin-III level in 
relation to disease severity, indicated by Braak tangle stage. Ang-III level was significantly increased 
in Braak stage V-VI compare to 0-II (P < 0.0001 using one-way ANOVA with Bonferroni post-hoc 
analysis). In A and B the bars represent the mean and SEM. (C-D) Scatterplots showing highly 
significant positive correlations between Ang-III level and (C) insoluble Aβ level and (D) parenchymal 
tau load. The best-fit linear regression lines (inner line) and 95% confidence intervals are 
superimposed. Each dot represents a single case. The green circles indicate controls and the red 
circles indicate AD cases. 
Figure 3. Aminopeptidase-A (AP-A) protein levels are significantly reduced in Alzheimer’s disease 
(AD) but enzyme activity is unaltered. (A) Bar charts showing significantly reduced AP-A level in AD 
(P < 0.0001 using an unpaired t-test) (B) AP-A level was significantly reduced in Braak stage V-VI 
compared to Braak stage 0-II (P < 0.0001 using one-way ANOVA with Bonferroni post-hoc analysis).  
(C-D) Bar charts show a trend towards higher AP-A enzyme activity in AD in relation to disease 
severity (despite reduced protein level), indicated by highest activity in Braak tangle stage V-VI, 
although the difference was not statistically significant. Bars represent the mean and SEM. 
Figure 4. Aminopeptidase-N (AP-N) enzyme activity is reduced in Alzheimer’s disease (AD) but 
protein levels are unaltered. (A-B) Bar charts showing unchanged AP-N levels in AD compared to 
age-matched controls in relation to disease stage severity. (C-D) Bar charts showing significantly 
lower AP-N activity in AD compared to age-matched controls (P < 0.05 using an unpaired t-test) and 
in relation to disease severity, indicated by lower activity in Braak tangle stage V-VI, although this 
difference was not statistically significant. Bars represent the mean and SEM. 
Figure 5. Aminopeptidase-A (AP-A) localisation in human brain tissue. AP-A distribution in the 
temporal neocortex (a and b, scale bars = 50µm) and subiculum (c, scale bar = 100µm) of an 
Alzheimer’s disease (AD) patient. AP-A also labelled cells in the temporal neocortex (d and f, scale 
bars = 50µm) and an area of focal white matter ischaemic damage (e, scale bar = 100µm) in controls. 
Prominent vascular labeling (g, scale bar = 50µm) and labeling was also present in the subiculum (h, 
scale bar = 100µm) of controls. AP-A immunolabeling was observed in macrophages and microglia in 
both AD cases and controls. Staining was also seen in these cell types in association with Aβ plaques. 
Occasional neuronal immunolabeling was seen in both AD cases and controls. High levels of labeling 
were seen in an area of focal white matter ischaemic damage (d and f) while prominent vascular 
labeling was present in some subjects.  
Figure 6. Aminopeptidase-N (AP-N) localisation in human brain tissue. AP-N distribution in the 
frontal neocortex (a), CA2 region of the hippocampus (b), temporal neocortex (c) and parietal 
neocortex (d) of an Alzheimer’s disease (AD) patient. AP-N also labelled some neurons, albeit with 
less intensity, in the frontal neocortex (e), CA2 region of the hippocampus (f), temporal neocortex (g) 
and parietal neocortex (h) of control subjects. No vessel staining was observed in any of the cases 
examined. Scale bar = 50µm for all sections. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Summary of demographics of control and AD cases 
 Age-at-death 
(years ± SD) 
Gender 
(Females:
Males) 
Post-mortem delay 
(hours ± SD) 
Braak tangle stage 
0-II     III-IV     V-VI 
Controls 
(n = 59) 
78.5 ± 10.0 22:37 43.8 ± 36  41        15         0 
AD 
( n = 90) 
78.5 ± 9.7 55:35 45.0 ± 25         0         13         77 
Braak Tangle stage score unavailable for 3 control case 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1: MRC identifiers 
Diagnosis MRC 
identifier 
Age-at-death 
(h) 
Gender Post-Mortem 
delay (h) 
Braak Tangle 
stage 
Control BBN_8639 62 M 4 0 
Control BBN_8644 84 M 72 3 
Control BBN_8651 95 F 46 2 
Control BBN_8671 78 F 24 2 
Control BBN_8682 83 M 80 3 
Control BBN_8684 71 M 25 1 
Control BBN_8691 82 F 35 3 
Control BBN_8700 64 M 12 2 
Control BBN_8702 58 M 20 0 
Control BBN_8703 64 M 16 0 
Control BBN_8706 72 M 42 1 
Control BBN_8707 80 M 106 3 
Control BBN_8708 90 M 45 2 
Control BBN_8709 83 M 86 2 
Control BBN_8712 81 F 103 2 
Control BBN_8714 64 M 23 2 
Control BBN_8717 77 M 55 1 
Control BBN_8722 78 M 12 2 
Control BBN_8723 80 M 67 3 
Control BBN_8725 73 M 36 2 
Control BBN_8728 88 F 62 2 
Control BBN_8731 70 M 50 2 
Control BBN_8732 76 F 106 2 
Control BBN_8735 88 F 72 0 
Control BBN_8739 93 F 18 2 
Control BBN_8741 80 F 92 0 
Control BBN_8749 88 F 28 2 
Control BBN_8751 82 M 30 2 
Control BBN_8756 84 M 48 3 
Control BBN_8757 90 M 48 2 
Control BBN_8759 75 M 48 2 
Control BBN_8768 78 F 22 1 
Control BBN_8770 89 F 15 2 
Control BBN_8776 73 M 33 1 
Control BBN_8779 69 M 66 2 
Control BBN_8835 73 F 59 1 
Control BBN_8883 90 M 40 3 
Control BBN_8888 89 M 91 2 
Control BBN_8898 83 F 24 2 
Control BBN_8923 82 M 3 2 
Control BBN_8949 79 M 24 . 
Control BBN_8956 43 F 12 . 
Control BBN_8957 76 F 12 . 
Control BBN_8961 84 F 17 1 
Control BBN_8964 82 F 37 2 
Control BBN_8966 53 M 7 3 
Control BBN_8980 72 F 24 0 
Control BBN_8983 78 M 48 1 
Control BBN_9012 81 M 3 2 
Control BBN_9016 82 M 56 2 
Control BBN_9028 76 M 23 2 
Control BBN_9038 82 F 96 3 
Control BBN_9086 77 M 10 3 
Control BBN_9092 75 M 6 3 
Control BBN_9217 93 F 53 3 
Control BBN_9256 84 F . 2 
Control BBN_9292 73 M 35 3 
Control BBN_9299 90 M 6 2 
Control BBN_9311 93 M 38 3 
AD BBN_8819 89 F 71 5 
AD BBN_8825 78 F 77 6 
AD BBN_8834 78 F 9 5 
AD BBN_8839 82 M 69 5 
AD BBN_8841 81 F 80 3 
AD BBN_8842 81 F 42 6 
AD BBN_8848 77 F 43 4 
AD BBN_8852 71 F 67 5 
AD BBN_8853 96 F 53 4 
AD BBN_8857 87 F 72 5 
AD BBN_8870 87 F 67 5 
AD BBN_8870 79 F 70 3 
AD BBN_8871 88 F 79 6 
AD BBN_8885 68 M 28 5 
AD BBN_8886 81 M 29 4 
AD BBN_8892 91 F 70 5 
AD BBN_8905 72 M 61 4 
AD BBN_8906 78 F 35 6 
AD BBN_8912 82 F 24 6 
AD BBN_8915 85 M 58 4 
AD BBN_8917 91 M 43 3 
AD BBN_8918 89 F 82 5 
AD BBN_8930 70 F 25 6 
AD BBN_8947 78 F 4 5 
AD BBN_8954 69 M 48 5 
AD BBN_8958 74 M 50 5 
AD BBN_8969 95 M 48 3 
AD BBN_8997 74 F 12 6 
AD BBN_9005 89 F 4 6 
AD BBN_9026 79 M 28 6 
AD BBN_9031 85 M 66 6 
AD BBN_9050 90 F 21 4 
AD BBN_9052 57 F 24 5 
AD BBN_9061 54 F 24 6 
AD BBN_9076 84 F 20 5 
AD BBN_9095 79 F 72 5 
AD BBN_9102 78 M 21 3 
AD BBN_9106 93 M 20 6 
AD BBN_9112 74 F 53 5 
AD BBN_9113 81 F 59 5 
AD BBN_9114 82 M 64 4 
AD BBN_9119 80 M 49 5 
AD BBN_9122 83 F 5 5 
AD BBN_9123 74 F 35 5 
AD BBN_9125 84 F 23 6 
AD BBN_9132 80 M 5 5 
AD BBN_9136 77 F 26 6 
AD BBN_9156 79 M 39 5 
AD BBN_9162 63 M 43 6 
AD BBN_9165 60 F 68 6 
AD BBN_9167 79 F 48 5 
AD BBN_9179 64 M 9 6 
AD BBN_9182 74 M 24 5 
AD BBN_9123 85 F 49 5 
AD BBN_9188 68 F 87 6 
AD BBN_9189 78 F 21 6 
AD BBN_9193 79 M 84 5 
AD BBN_9194 89 F 39 5 
AD BBN_9198 77 F 14 6 
AD BBN_9200 84 M 64 5 
AD BBN_9201 65 M 90 6 
AD BBN_9205 85 F 85 6 
AD BBN_9207 80 F 71 6 
AD BBN_9209 73 F 38 5 
AD BBN_9212 65 F 22 6 
AD BBN_9221 68 M 61 6 
AD BBN_9222 90 M 32 6 
AD BBN_9243 88 F 75 5 
AD BBN_9248 83 F 85 6 
AD BBN_9259 47 F 54 6 
AD BBN_9261 83 M 48 5 
AD BBN_9263 74 M 48 5 
AD BBN_9265 60 F 5 6 
AD BBN_9269 83 M 99 4 
AD BBN_9274 78 M 49 6 
AD BBN_9275 87 M 36 6 
AD BBN_9284 76 F 44 6 
AD BBN_9291 62 M 25 6 
AD BBN_9293 78 M 50 6 
AD BBN_9295 85 M 50 6 
AD BBN_9256 98 F 21 5 
AD BBN_9298 83 F 32 6 
AD BBN_9301 84 F 11 5 
AD BBN_9303 69 M 12 5 
AD BBN_9304 61 M 38 5 
AD BBN_9309 88 F 88 5 
AD BBN_9310 85 F 102 6 
AD BBN_9315 67 F 24 6 
AD BBN_9320 87 F 28 6 
AD BBN_9323 84 F 21 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Angiotensin-II (Ang-II) and angiotensin-III (Ang-III) levels are not influenced 
by age-at-death or post-mortem (PM) delay. (A-B) Scatterplots showing no significant correlation 
between Ang-II and age-at-death and PM delay. (C-D)  Scatterplots showing no significant 
correlation between Ang-III and age-at-death and PM delay. The best-fit linear regression lines (inner 
line) and 95% confidence intervals are superimposed. Each dot represents a single case. The green 
circles indicate controls and the red circles indicate AD cases. 
Supplementary Figure 2. Aminopeptidase-A (AP-A) and aminopeptidase-N (AP-N) level and enzyme 
activity are not influenced by age-at-death or post-mortem (PM) delay. (A-D) Scatterplots showing 
no significant correlation between AP-A level or AP-A enzyme activity with age-at-death and PM 
delay. (E-H) Scatterplots showing no significant correlation between AP-A level or AP-A enzyme 
activity with age-at-death and PM delay. The best-fit linear regression lines (inner line) and 95% 
confidence intervals are superimposed. Each dot represents a single case. The green circles indicate 
controls and the red circles indicate AD cases. 
Supplementary Figure 3. Ang-II, Ang-III and AP-A and AP-N level and activity is not influenced by 
gender. Bar charts showing gender specific levels of (A) Ang-II and (B) Ang-III in AD and controls. 
Ang-II levels were higher in females in both AD and controls but the difference was not statistically 
significant; Ang-III levels are unaltered between genders. Bar charts showing gender specific (C-D) 
AP-A levels and activities and (E-F) AP-N levels and activities which were unaltered in AD and 
controls. The bars represent the mean and SEM. * P < 0.05; ** P < 0.01; *** P < 0.001 and **** P < 
0.0001 
